Good news for Precision Bio? Investors ready again for IPos
The IPO market has been a dud for months. But that’s about to change. And that could mean good news for Durham-based Precision BioSciences.
Read More
IPO
Government shutdown is not stopping the IPO market
The US Securities and Exchange Commission is running with limited staff because of the partial government shutdown. But that’s not stopping companies looking to go public on Wall Street.
Read More
Startups remain hopeful about IPOs as an exit for their firms, survey finds
Startup founders are yet again bullish on the IPO market, the State of Startups 2018 survey from First Round discovered.
Read More
IPO is latest step for ‘superstar scientist’ Joe DeSimone-founded Liquidia
Liquidia Technologies has enjoyed success in R&D, but now can it find success for the bottom line?
Read MoreCharlotte marketing startup Level Brands raises $12M in IPO
Level Brands Inc., a licensing and marketing company focused on corporate brand management, closed its initial public offering on Thursday and shares are down 8 percent Friday, the first day of trading on the NYSE. Level Brands began trading at $6 per share, but shares fell to $5.52. The company priced its IPO at $6 per share, selling 2 million shares, according to a filing with the Securities and Exchange Commission. The company’s stock trades under the ticker LEVB. Tracking Level Brands’ quick route to an IPO Underwriters for the offering were Joseph Gunnar and Co. LLC and TriPoint Global...
Read MoreRaleigh-based Bandwidth ups IPO target to $101M
Raleigh-based Bandwidth is upping the target for its initial public offering to $101 million, according to a securities filing. In the filing made Monday evening, Bandwidth also set a target share price of $22 million. Two weeks ago in its initial filing the privately held company set an IPO target of $85 million. Bandwidth to use the money from the IPO for expansion of their sales, marketing and research and development. The company also plans to use the money for future strategic acquisitions although there are not agreements or commitments withstanding. The initial Form S-1 filing had not listed...
Read More
RTP-based G1 Therapeutics files for $115M IPO
G1 Therapeutics Inc., a clinical-stage biopharmaceutical company based in the Research Triangle Park, filed Thursday for an initial public offering of $115 million. G1 Therapeutics focuses on the discovery and development of novel therapeutics for the treatment of cancer. It plans to use proceeds from the offering to advance...
Read MoreIs Appia Going Public?
For all the recent talk about the top of the funnel in the startup universe, both locally and nationwide, it’s nice when you get to talk about an exit—and make no mistake, there are a handful of companies in the Triangle, you know who I’m talking about, the ChannelAdvisors and the Appias, who are in the conversation, if not already in position, to either go public or get acquired for a significant sum of money. So I’m totally speculating here, but Appia just hired veteran acquisition guru Tim Oakley as their CFO. In fact, they’re announcing this right now....
Read More
